Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Ehab L. Atallah MD

Ehab L. Atallah MD profile photo picture


Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Hematology

Member of the Cancer Center

Publications (84)

  • Patient-Reported Functional Outcomes in Patients with Chronic Myeloid Leukemia after Stopping Tyrosine Kinase Inhibitors. (Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE) J Natl Cancer Inst 2021 Sep 07 PMID: 34491344 09/08/2021    
  • Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E) Bone Marrow Transplantation August 2021;56(8):1998-2004 SCOPUS ID: 2-s2.0-85103674051 08/01/2021    
  • Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes? (Badar T, Atallah E) Expert Opin Investig Drugs 2021 Jun;30(6):665-673 PMID: 33836635 SCOPUS ID: 2-s2.0-85104939879 04/11/2021    
  • Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. (Badar T, Szabo A, Litzow M, Burkart M, Yurkiewicz I, Dinner S, Hefazi M, Shallis RM, Podoltsev N, Patel AA, Curran E, Wadleigh M, Balasubramanian S, Yang J, Arslan S, Aldoss I, Mattison R, Cenin D, Siebenaller C, Advani A, Liedtke M, Atallah E) Bone Marrow Transplant 2021 08;56(8):1998-2004 PMID: 33824440 SCOPUS ID: 2-s2.0-85103674051 04/08/2021    
  • Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making. (Atallah EL) Best Pract Res Clin Haematol 2021 03;34(1):101240 PMID: 33762095 SCOPUS ID: 2-s2.0-85100148584 03/26/2021    
  • Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates. (Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V) Leuk Lymphoma 2021 07;62(7):1730-1739 PMID: 33648418 SCOPUS ID: 2-s2.0-85110241807 03/03/2021    
  • Why isn't there a one-size-fits-all approach for relapsed/refractory acute myeloid leukemia? Insights into different variables for decision-making (Atallah EL) Best Practice and Research: Clinical Haematology March 2021;34(1) SCOPUS ID: 2-s2.0-85100148584 03/01/2021    
  • Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. (Badar T, Szabo A, Dinner S, Liedtke M, Burkart M, Shallis RM, Yurkiewicz IR, Kuo E, Khan MA, Balasubramanian S, Yang J, Hefazi M, Podoltsev N, Patel A, Curran E, Wang A, Arslan S, Aldoss I, Siebenaller C, Mattison RJ, Litzow MR, Wadleigh M, Advani AS, Atallah E) Cancer 2021 Apr 01;127(7):1039-1048 PMID: 33259056 SCOPUS ID: 2-s2.0-85096971225 12/02/2020    
  • Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. (Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, Horowitz M, Flynn KE) JAMA Oncol 2021 Jan 01;7(1):42-50 PMID: 33180106 PMCID: PMC7662490 SCOPUS ID: 2-s2.0-85096163350 11/13/2020       3 Citations
  • Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? (Atallah E, Schiffer CA) Haematologica 2020 12 01;105(12):2738-2745 PMID: 33054106 PMCID: PMC7716356 SCOPUS ID: 2-s2.0-85093538868 10/16/2020    
  • Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia. (Mushtaq MU, Harrington AM, Chaudhary SG, Michaelis LC, Carlson KB, Abedin S, Runass L, Callander NS, Fallon MJ, Juckett M, Hall AC, Hematti P, Mattison RJ, Atallah EL, Guru Murthy GS) Leuk Lymphoma 2021 01;62(1):158-166 PMID: 32951486 SCOPUS ID: 2-s2.0-85091139710 09/22/2020       3 Citations
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M) Leukemia Research August 2020;95 SCOPUS ID: 2-s2.0-85085967271 08/01/2020       11 Citations
  • Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase—A real world study (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leukemia Research July 2020;94 SCOPUS ID: 2-s2.0-85084755644 07/01/2020       1 Citation
  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M) Leuk Res 2020 08;95:106385 PMID: 32521310 SCOPUS ID: 2-s2.0-85085967271 06/11/2020       11 Citations
  • Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. (Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E) Blood Adv 2020 05 26;4(10):2308-2316 PMID: 32453836 PMCID: PMC7252553 SCOPUS ID: 2-s2.0-85086878601 05/27/2020       4 Citations
  • Reducing venous thrombosis with antithrombin supplementation in patients undergoing treatment for ALL with Peg-asparaginase-A real world study. (George G, Rezazadeh A, Zook F, Pearl N, McCoy C, Carlson K, Runaas L, Abedin S, Guru Murthy GS, Michaelis LC, Atallah E, Baumann-Kreuziger L) Leuk Res 2020 07;94:106368 PMID: 32442786 SCOPUS ID: 2-s2.0-85084755644 05/23/2020       1 Citation
  • Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin. (Badar T, Szabo A, Wadleigh M, Liedtke M, Arslan S, Siebenaller C, Aldoss I, Schultz E, Hefazi M, Litzow MR, Kuo E, Wang A, Curran E, Shallis RM, Podoltsev N, Balasubramanian S, Yang J, Mattison R, Burkart M, Dinner S, Advani A, Atallah E) Clin Lymphoma Myeloma Leuk 2020 08;20(8):556-560.e2 PMID: 32291234 SCOPUS ID: 2-s2.0-85083004098 04/16/2020       5 Citations
  • Improving Outcomes of Acute Promyelocytic Leukemia in the Current Era: Analysis of the SEER Database. (Guru Murthy GS, Szabo A, Michaelis L, Carlson KS, Runaas L, Abedin S, Atallah E) J Natl Compr Canc Netw 2020 02;18(2):169-175 PMID: 32023530 SCOPUS ID: 2-s2.0-85079065513 02/06/2020       9 Citations
  • Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. (Jain N, Stock W, Zeidan A, Atallah E, McCloskey J, Heffner L, Tomlinson B, Bhatnagar B, Feingold J, Ungar D, Chao G, Zhang X, Qin Y, Havenith K, Kantarjian H, Wieduwilt MJ) Blood Adv 2020 02 11;4(3):449-457 PMID: 32012214 PMCID: PMC7013258 SCOPUS ID: 2-s2.0-85082200332 02/06/2020       14 Citations
  • In Reply. (Flynn KE, Vanness DJ, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2020 04;25(4):e744-e745 PMID: 31873972 PMCID: PMC7160403 SCOPUS ID: 2-s2.0-85076804489 12/25/2019    
  • Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. (Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, Horowitz MM, Rizzo JD) JAMA Oncol 2020 04 01;6(4):486-493 PMID: 31830234 PMCID: PMC6990739 SCOPUS ID: 2-s2.0-85076620276 12/13/2019       13 Citations
  • Musculoskeletal Pain in Patients With Chronic Myeloid Leukemia After Tyrosine Kinase Inhibitor Therapy Cessation. (Kota V, Atallah E) Clin Lymphoma Myeloma Leuk 2019 08;19(8):480-487 PMID: 31171474 SCOPUS ID: 2-s2.0-85066428575 06/07/2019       4 Citations
  • Patients' perspectives on the definition of cure in chronic myeloid leukemia. (Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E) Leuk Res 2019 05;80:40-42 PMID: 30955853 SCOPUS ID: 2-s2.0-85063942202 04/09/2019       1 Citation
  • Exploring Patient Decision Making Regarding Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. (Flynn KE, Myers JM, D'Souza A, Schiffer CA, Thompson JE, Atallah E) Oncologist 2019 09;24(9):1253-1258 PMID: 30944185 PMCID: PMC6738285 SCOPUS ID: 2-s2.0-85063940883 04/05/2019       6 Citations
  • Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. (Garcia-Manero G, Abaza Y, Takahashi K, Medeiros BC, Arellano M, Khaled SK, Patnaik M, Odenike O, Sayar H, Tummala M, Patel P, Maness-Harris L, Stuart R, Traer E, Karamlou K, Yacoub A, Ghalie R, Giorgino R, Atallah E) Blood Adv 2019 02 26;3(4):508-518 PMID: 30760466 PMCID: PMC6391673 SCOPUS ID: 2-s2.0-85061620083 02/15/2019       27 Citations
  • Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. (Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL) Leuk Lymphoma 2019 06;60(6):1476-1484 PMID: 30668234 SCOPUS ID: 2-s2.0-85060599029 01/23/2019       3 Citations
  • Treatment-Free Remission in CML: the US Perspective. (Guru Murthy GS, Atallah E) Curr Hematol Malig Rep 2019 02;14(1):56-61 PMID: 30645715 SCOPUS ID: 2-s2.0-85060169494 01/16/2019       8 Citations
  • Incidence and survival of T-cell acute lymphoblastic leukemia in the United States. (Guru Murthy GS, Pondaiah SK, Abedin S, Atallah E) Leuk Lymphoma 2019 05;60(5):1171-1178 PMID: 30407885 SCOPUS ID: 2-s2.0-85057299329 11/09/2018       6 Citations
  • Incorporating newer agents in the treatment of acute myeloid leukemia. (Raj RV, Abedin SM, Atallah E) Leuk Res 2018 11;74:113-120 PMID: 30401522 SCOPUS ID: 2-s2.0-85055577100 11/08/2018       6 Citations
  • Implementation and evaluation of high-dose methotrexate administration guidelines. (Nowak TJ, Lorge AH, Rein LE, Canadeo AM, Frank JP, Samanas LC, Urmanski AM, Atallah EL) J Oncol Pharm Pract 2019 Oct;25(7):1675-1681 PMID: 30360674 SCOPUS ID: 2-s2.0-85059348123 10/27/2018       1 Citation
  • Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. (Guru Murthy GS, Pemmaraju N, Atallah E) Leuk Res 2018 10;73:21-23 PMID: 30189324 SCOPUS ID: 2-s2.0-85052637608 09/07/2018       29 Citations
  • Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy. (Voshtina E, Huang H, Raj R, Atallah E) Case Rep Hematol 2018;2018:6514604 PMID: 30155323 PMCID: PMC6092972 08/30/2018    
  • Incidence and survival of therapy related myeloid neoplasm in United States. (Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E) Leuk Res 2018 08;71:95-99 PMID: 30048839 SCOPUS ID: 2-s2.0-85050226100 07/27/2018       12 Citations
  • Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. (Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KE) BMC Cancer 2018 04 02;18(1):359 PMID: 29609532 PMCID: PMC5879565 SCOPUS ID: 2-s2.0-85044841612 04/04/2018       11 Citations
  • Early Fluorescence in situ Hybridization Assessment during Acute Myeloid Leukemia Induction Chemotherapy. (Schneidewend R, Hosking P, Brazauskas R, Peterson J, Beaudin C, Michaelis L, Atallah E, Hari P, Carlson K) Acta Haematol 2018;139(3):171-175 PMID: 29597188 PMCID: PMC6388419 SCOPUS ID: 2-s2.0-85045039013 03/30/2018    
  • Dasatinib dose management for the treatment of chronic myeloid leukemia. (Talpaz M, Saglio G, Atallah E, Rousselot P) Cancer 2018 04 15;124(8):1660-1672 PMID: 29370463 PMCID: PMC5901015 SCOPUS ID: 2-s2.0-85045130913 01/26/2018       12 Citations
  • Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? (Atallah E, Ritchie E) Expert Opin Pharmacother 2018 02;19(2):79-81 PMID: 29308683 SCOPUS ID: 2-s2.0-85041333482 01/09/2018       1 Citation
  • Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation. (Narra RK, Flynn KE, Atallah E) Curr Hematol Malig Rep 2017 10;12(5):415-423 PMID: 28944397 PMCID: PMC6045428 SCOPUS ID: 2-s2.0-85029897925 09/26/2017       4 Citations
  • Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: A large database analysis. (Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KS, Hamadani M, Fenske TS, Hari P, Atallah E, Dhakal B) Am J Hematol 2017 Sep;92(9):E563-E565 PMID: 28631379 SCOPUS ID: 2-s2.0-85021972988 06/21/2017       2 Citations
  • Chronic Myeloid Leukemia: What Every Practitioner Needs to Know in 2017. (Khoury HJ, Williams LA, Atallah E, Hehlmann R) Am Soc Clin Oncol Educ Book 2017;37:468-479 PMID: 28561719 SCOPUS ID: 2-s2.0-85041303313 06/01/2017       10 Citations
  • Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. (Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP) J Clin Oncol 2017 Aug 20;35(24):2745-2753 PMID: 28486043 PMCID: PMC5562170 SCOPUS ID: 2-s2.0-85028505702 05/10/2017       123 Citations
  • Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. (Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M) Biol Blood Marrow Transplant 2017 Aug;23(8):1295-1302 PMID: 28412518 SCOPUS ID: 2-s2.0-85019639994 04/17/2017       7 Citations
  • Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. (Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U, Steensma DP, Kambhampati S, Kreuzer KA, Godley LA, Atallah E, Collins R Jr, Kantarjian H, Jabbour E, Wilhelm FE, Azarnia N, Silverman LR, ONTIME study investigators) Lancet Oncol 2016 Apr;17(4):496-508 PMID: 26968357 SCOPUS ID: 2-s2.0-84959931622 03/13/2016       101 Citations
  • Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. (Flynn KE, Atallah E) Curr Hematol Malig Rep 2016 Apr;11(2):80-5 PMID: 26879546 PMCID: PMC4860261 SCOPUS ID: 2-s2.0-84958241812 02/18/2016       23 Citations
  • A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. (Kantarjian HM, Lioure B, Kim SK, Atallah E, Leguay T, Kelly K, Marolleau JP, Escoffre-Barbe M, Thomas XG, Cortes J, Jabbour E, O'Brien S, Bories P, Oprea C, Hatteville L, Dombret H) Clin Lymphoma Myeloma Leuk 2016 Mar;16(3):139-45 PMID: 26775883 PMCID: PMC5557033 SCOPUS ID: 2-s2.0-84958922276 01/19/2016       44 Citations
  • Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms. (Hanif A, Hari PN, Atallah E, Carlson KS, Pasquini MC, Michaelis LC) Bone Marrow Transplant 2016 Apr;51(4):617-8 PMID: 26726940 SCOPUS ID: 2-s2.0-84953295752 01/05/2016       13 Citations
  • Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis. (Verstovsek S, Atallah E, Mascarenhas J, Sun H, Montgomery M, Gupta V, Mesa R, Gotlib J) Leukemia 2016 06;30(6):1413-5 PMID: 26526986 PMCID: PMC4895165 SCOPUS ID: 2-s2.0-84948424356 11/04/2015       5 Citations
  • Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. (Cornell RF, Zhong X, Arce-Lara C, Atallah E, Blust L, Drobyski WR, Fenske TS, Pasquini MC, Rizzo JD, Saber W, Hari PN) Bone Marrow Transplant 2015 Jul;50(7):914-7 PMID: 25915809 SCOPUS ID: 2-s2.0-84934862607 04/29/2015       21 Citations
  • Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. (Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, Sun W, Sandor V, Gotlib J) Clin Lymphoma Myeloma Leuk 2015 Apr;15(4):214-221.e1 PMID: 25682576 PMCID: PMC4418454 SCOPUS ID: 2-s2.0-84925412377 02/16/2015       41 Citations
  • Large granular lymphocytic leukemia presenting late after solid organ transplantation: a case series of four patients and review of the literature. (Kataria A, Cohen E, Saad E, Atallah E, Bresnahan B) Transplant Proc 2014 Dec;46(10):3278-81 PMID: 25240311 SCOPUS ID: 2-s2.0-84926339267 09/23/2014       3 Citations
  • Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension. (Yan M, Geyer H, Mesa R, Atallah E, Callum J, Bartoszko J, Yee K, Maganti M, Wong F, Gupta V) Clin Lymphoma Myeloma Leuk 2015 Jan;15(1):e1-5 PMID: 25027569 PMCID: PMC4361182 SCOPUS ID: 2-s2.0-84934440451 07/17/2014       11 Citations
  • Myelodysplastic syndromes in the United States: an update for clinicians. (Troy JD, Atallah E, Geyer JT, Saber W) Ann Med 2014 Aug;46(5):283-9 PMID: 24716735 SCOPUS ID: 2-s2.0-84905448514 04/11/2014       17 Citations
  • Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT). (Atallah E, Bylow K, Troy J, Saber W) Curr Hematol Malig Rep 2014 Mar;9(1):57-65 PMID: 24398726 PMCID: PMC4031643 SCOPUS ID: 2-s2.0-84896710555 01/09/2014       12 Citations
  • Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes. (Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA) Onco Targets Ther 2013;7:13-21 PMID: 24368888 PMCID: PMC3869911 SCOPUS ID: 2-s2.0-84890462687 12/26/2013       33 Citations
  • Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. (Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, Smith SE, Doyle LA, Stadler WM, Larson RA, Stock W, Odenike O) Clin Cancer Res 2014 Jan 15;20(2):490-8 PMID: 24178622 PMCID: PMC4310865 SCOPUS ID: 2-s2.0-84892716958 11/02/2013       80 Citations
  • Clarifying the use of ruxolitinib in patients with myelofibrosis. (Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO) Oncology (Williston Park) 2013 Jul;27(7):706-14 PMID: 23977767 SCOPUS ID: 2-s2.0-84880293714 08/28/2013       9 Citations
  • Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). (Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM) Blood 2013 Sep 12;122(11):1974-82 PMID: 23847196 PMCID: PMC3772501 SCOPUS ID: 2-s2.0-84887389178 07/13/2013       61 Citations
  • Emerging drugs for myelofibrosis. (Atallah E, Verstovsek S) Expert Opin Emerg Drugs 2012 Dec;17(4):555-70 PMID: 23186315 PMCID: PMC5009610 SCOPUS ID: 2-s2.0-84870443079 11/29/2012       5 Citations
  • Clinical regression of squamous cell carcinoma and keratoacanthomas in a patient treated with a hypomethylating agent. (Randhawa J, Wong S, Atallah E, Olasz E) Int J Dermatol 2014 Jan;53(1):e13-4 PMID: 22998756 SCOPUS ID: 2-s2.0-84890794842 09/25/2012       2 Citations
  • Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. (Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S) J Hematol Oncol 2012 Aug 01;5:43 PMID: 22852872 PMCID: PMC3464878 SCOPUS ID: 2-s2.0-84864416539 08/03/2012       24 Citations
  • Myeloproliferative neoplasms. (Kim J, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):177-94 PMID: 22449367 SCOPUS ID: 2-s2.0-84863382779 03/28/2012       9 Citations
  • Chronic myelogenous leukemia for primary care physicians. (Torgerson SR, Haddad RY, Atallah E) Dis Mon 2012 Apr;58(4):168-76 PMID: 22449366 SCOPUS ID: 2-s2.0-84858824580 03/28/2012       8 Citations
  • Nilotinib cardiac toxicity: should we still be concerned? (Atallah E) Leuk Res 2011 May;35(5):577-8 PMID: 21333353 SCOPUS ID: 2-s2.0-79954594715 02/22/2011       9 Citations
  • Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. (Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J) Am J Hematol 2010 Aug;85(8):579-83 PMID: 20578198 PMCID: PMC3800118 SCOPUS ID: 2-s2.0-77955480515 06/26/2010       5 Citations
  • Recurrent deep vein thrombosis and pulmonary embolism in a young man with Klinefelter's syndrome and heterozygous mutation of MTHFR-677C>T and 1298A>C. (Angel JR, Parker S, Sells RE, Atallah E) Blood Coagul Fibrinolysis 2010 Jun;21(4):372-5 PMID: 20449891 SCOPUS ID: 2-s2.0-77951915862 05/08/2010       9 Citations
  • Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. (Bilgi N, Bell K, Ananthakrishnan AN, Atallah E) Ann Pharmacother 2010 May;44(5):926-8 PMID: 20332334 SCOPUS ID: 2-s2.0-77951554533 03/25/2010       73 Citations
  • Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. (Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH) Leuk Lymphoma 2010 Mar;51(3):481-7 PMID: 20141431 SCOPUS ID: 2-s2.0-79954619318 02/10/2010       4 Citations
  • Resolution of rheumatoid arthritis symptoms with imatinib mesylate. (Vernon MR, Pearson L, Atallah E) J Clin Rheumatol 2009 Aug;15(5):267 PMID: 19654496 SCOPUS ID: 2-s2.0-69549097990 08/06/2009       10 Citations
  • Practical considerations for the management of patients in the tyrosine kinase inhibitor era. (O'Dwyer M, Atallah E) Semin Hematol 2009 Apr;46(2 Suppl 3):S16-21 PMID: 19621545 SCOPUS ID: 2-s2.0-63249106651 07/23/2009       12 Citations
  • Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. (Atallah E, Verstovsek S) Expert Rev Anticancer Ther 2009 May;9(5):663-70 PMID: 19445582 PMCID: PMC5176249 SCOPUS ID: 2-s2.0-68149160994 05/19/2009       24 Citations
  • Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. (Nand R, Bryke C, Kroft SH, Divgi A, Bredeson C, Atallah E) Leuk Res 2009 Aug;33(8):1144-6 PMID: 19394693 SCOPUS ID: 2-s2.0-67349165083 04/28/2009       26 Citations
  • Treatment strategies in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Cancer Invest 2008 Mar;26(2):208-16 PMID: 18259954 SCOPUS ID: 2-s2.0-38949120072 02/09/2008       9 Citations
  • Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. (Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek S) Leukemia 2008 Jun;22(6):1295-8 PMID: 18059483 SCOPUS ID: 2-s2.0-45149121653 12/07/2007       25 Citations
  • Use of hypomethylating agents in myelodysplastic syndromes. (Atallah E, Garcia-Manero G) Clin Adv Hematol Oncol 2007 Jul;5(7):544-52 PMID: 17679928 SCOPUS ID: 2-s2.0-34848895438 08/08/2007       6 Citations
  • Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. (Atallah E, Cortes J, O'Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H) Blood 2007 Nov 15;110(10):3547-51 PMID: 17673605 SCOPUS ID: 2-s2.0-36348930556 08/04/2007       62 Citations
  • Congestive heart failure is a rare event in patients receiving imatinib therapy. (Atallah E, Durand JB, Kantarjian H, Cortes J) Blood 2007 Aug 15;110(4):1233-7 PMID: 17449798 SCOPUS ID: 2-s2.0-34548030470 04/24/2007       195 Citations
  • Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. (Atallah E, Kantarjian H, Cortes J) Clin Lymphoma Myeloma 2007 Mar;7 Suppl 3:S105-12 PMID: 17382019 SCOPUS ID: 2-s2.0-34249653546 03/27/2007       26 Citations
  • Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase. (Atallah E, Cortes J) Curr Opin Hematol 2007 Mar;14(2):138-44 PMID: 17255791 SCOPUS ID: 2-s2.0-33846591021 01/27/2007       3 Citations
  • In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. (Atallah E, Kantarjian H, Cortes J) Nat Med 2007 Jan;13(1):14; author reply 15-6 PMID: 17206119 SCOPUS ID: 2-s2.0-33846086176 01/09/2007       33 Citations
  • The role of decitabine in the treatment of myelodysplastic syndromes. (Atallah E, Kantarjian H, Garcia-Manero G) Expert Opin Pharmacother 2007 Jan;8(1):65-73 PMID: 17163808 SCOPUS ID: 2-s2.0-33846078174 12/14/2006       24 Citations
  • Agent Orange, prostate cancer irradiation and acute promyelocyic leukemia (APL): is there a link? (Atallah E, Schiffer CA) Leuk Res 2007 May;31(5):720-1 PMID: 16956658 SCOPUS ID: 2-s2.0-34147180942 09/08/2006       2 Citations
  • Granulocyte transfusion. (Atallah E, Schiffer CA) Curr Opin Hematol 2006 Jan;13(1):45-9 PMID: 16319687 SCOPUS ID: 2-s2.0-33644848150 12/02/2005       34 Citations
  • Treatment of metastatic malignant melanoma. (Atallah E, Flaherty L) Curr Treat Options Oncol 2005 May;6(3):185-93 PMID: 15869730 SCOPUS ID: 2-s2.0-21744439869 05/05/2005       151 Citations
  • Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy. (Atallah E, Talpaz M, O'brien S, Rios MB, Guo JQ, Arlinghaus R, Fernandes-Reese S, Kantarjian H) Cancer 2002 Jun 01;94(11):2996-9 PMID: 12115389 SCOPUS ID: 2-s2.0-0036604263 07/13/2002       17 Citations
  • Last update: 10/15/2021